MetalloBio is developing the first completely new classes of antibiotics to emerge from R&D in ~50 years. The company has two synthetic inorganic chemistry platforms each with an entirely novel antimicrobial molecular architecture not seen in this field before. Broad-spectrum compounds of the "DiRu" class are in development to treat respiratory infections associated with cystic fibrosis, hospital-acquired pneumonia, and ventilator-associated pneumonia. Compounds of the "MonoRu" class are reserved for non-pharmaceutical applications: as coatings for medical devices. DiRu compounds have a pluri-modal activity with at least two rapid killing activities, one of which implicates a novel target. MonoRu compounds have a distinct mode of action related to DNA metabolism. Both series are effective against all of the so-called ESKAPE pathogens, identified by the WHO as being responsible for the highest incidence bacterial infections and mortalities globally, accounting for about 75% of all hospital infections. MetalloBio's compounds are active against Gram positive and Gram negative bacteria and show no detectable onset of genetic resistance upon 2 months' continuous exposure to several pathogenic strains. They can penetrate and disrupt biofilms. To date, there is no evidence of appreciable toxicity in vitro or in in vivo studies (moth larvae, mice) and the compounds show a 50- to 100-fold therapeutic index. The company's commercial strategy is to partner pharmaceutical development in the early to mid-clinical stage. The company is also making compound and coating formulations available under licence to medical technology companies developing e.g. coated catheters or functionalised orthopaedic devices. Current financing and runway reflect over $2 million in non-dilutive funding raised so far. MetalloBio is interested in talking to potential investors for a Series A round (expected Q4 2024); and to potential pharmaceutical company partners and medtech licensees.